There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Opus Genetics (IRD – Research Report), Tactile ...
Opus Genetics (IRD) announced that the first pediatric patient was dosed in its ongoing Phase 1/2 clinical trial evaluating OPGx-LCA5, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback